CRISPR-Cas systems have transformed genetic research with their ability to precisely target and edit DNA sequences. However, clinical applications of CRISPR-based therapies largely remain ex vivo, editing cells outside the patient’s body before reintroduction. This limitation arises because the most accurate and safe gene editors are too large to be packaged into viral vectors—like adeno-associated viruses (AAVs)—which have a strict payload capacity of approximately 1,000 amino acids. To address this, researchers have sought smaller nucleases capable of fitting inside these vectors while maintaining robust editing capabilities.

In this study, the team at the University of Texas zeroed in on a naturally occurring bacterial nuclease called Al3Cas12f, belonging to a family of compact enzymes known as Cas12f. These proteins are considerably smaller—ranging from 400 to 700 amino acids—compared to conventional CRISPR nucleases. Despite their promising size, previous Cas12f enzymes exhibited limited editing activity within human cells, particularly due to the complex and dynamic cellular environment that challenges nuclease stability and efficiency.

Through detailed biochemical and structural investigation enhanced by cryo-electron microscopy, the researchers elucidated the unique molecular architecture of Al3Cas12f. Their analyses showcased an unusually large and stable interface among the enzyme’s subunits, ensuring a preassembled, highly stable protein complex that can efficiently engage DNA targets soon after synthesis. This intrinsic stability is pivotal, as transient complexes often fail to achieve consistent editing outcomes in live cells.

Yet, initial testing of the wild-type Al3Cas12f revealed that while its editing efficiency surpassed other Cas12f variants, it still struggled to modify certain genomic sequences effectively. To optimize performance, the scientists employed rational protein engineering, exploiting structural insights to design mutations that could enhance DNA binding affinity and catalytic turnover. This effort culminated in an engineered variant dubbed Al3Cas12f RKK, which demonstrated remarkable improvements in gene-editing efficiency.

The Al3Cas12f RKK nuclease was introduced into human cells derived from leukemia patients, targeting genes implicated in a spectrum of debilitating diseases such as cancer, atherosclerosis, and amyotrophic lateral sclerosis (ALS). The results were staggering: editing efficiency increased from less than 10% with the native enzyme to exceeding 80% across multiple genomic targets. Achieving such high efficiency in a compact nuclease now suitable for AAV packaging paves the way for direct gene therapy applications that were previously unattainable.

Critical to the success of Al3Cas12f RKK is its compatibility with viral delivery vectors widely used in clinical settings. AAV platforms are heralded for their safety and tissue specificity, but their limited cargo capacity has long constrained therapeutic gene editing. The development of a nuclease that not only fits within these size constraints but also excels functionally in the challenging milieu of human cells represents a profound leap forward in the quest for in vivo gene editing.

The research team utilized a synergistic approach, combining high-resolution structural biology, machine learning models, and functional cellular experiments. Cryo-electron microscopy provided atomic-level details of the enzyme-DNA complexes, while computational techniques simulated the dynamics of nuclease operation. This integrated methodology revealed structural elements underpinning enhanced DNA recognition and catalysis, guiding the targeted mutation strategy to create the RKK variant.

Looking ahead, the University of Texas researchers plan to conduct comprehensive in vivo studies to evaluate the performance of Al3Cas12f RKK when delivered through AAV vectors into animal models. Success in these endeavors would signify a critical translational milestone, bringing the promise of efficient, site-specific gene editing therapies for diverse genetic disorders such as muscular dystrophy, cancer, and neurodegenerative diseases ever closer to clinical reality.

David Taylor, professor of molecular biosciences and co-author, emphasized the broader implications of this discovery: “The identification of a compact, highly efficient nuclease capable of robust editing inside human cells sets a new standard for gene therapy tools. Our findings lay the foundation for customizable CRISPR systems that fulfill the exacting size and function parameters necessary for safe and effective in vivo applications.”

The innovation holds transformative potential not only in therapeutic gene editing but also in advancing biotechnological tools for fundamental genetic research, including model organism studies and functional genomics. By pushing the limits of protein engineering and delivery technologies, this research opens avenues for safer, more precise genetic interventions that could be administered directly to patients without invasive cell extraction procedures.

Importantly, funding from NIH’s National Institute of General Medical Sciences (NIGMS) supported this work, underscoring the critical role of public investment in basic and translational biomedical research. NIGMS acting director Erica Brown remarked, “Smart delivery of gene-editing systems is a powerful notion with broad clinical implications, and this basic science finding takes us a significant step toward that future.”

This cutting-edge study not only advances the frontiers of CRISPR technology but also addresses a pressing bottleneck in genetic medicine—the need for compact, reliable gene-editing tools that can be delivered efficiently within the human body. As gene therapy continues to evolve, engineered nucleases like Al3Cas12f RKK offer tangible hope for treating previously intractable genetic diseases through precise genomic interventions.

Subject of Research: Cells

Article Title: Comparative characterization of Cas12f orthologs reveals mechanistic features underlying enhanced genome editing efficiency

News Publication Date: April 13, 2026

Web References: https://www.nature.com/articles/s41594-026-01788-6

References: 10.1038/s41594-026-01788-6

Image Credits: University of Texas at Austin

Keywords

Gene editing, Gene therapy, CRISPRs, Genome editing

Osteopetrosis arises from inherited mutations that impair the resorptive activity of osteoclasts, specialized cells responsible for breaking down bone matrix to maintain healthy bone remodeling. The failure of osteoclast function disrupts the normal architecture of the BM niche, notably hampering the crucial homing and engraftment of HSPCs. This phenomenon leads to an accumulation of circulating HSPCs (cHSPCs) in peripheral blood due to their inability to properly populate the BM microenvironment, further exacerbating hematopoietic deficiencies. Early intervention is vital since progressive bone marrow failure severely limits treatment alternatives such as bone marrow transplantation.

Capitalizing on the window of opportunity presented shortly after birth, the novel LV gene transfer model strategically harnesses in vivo delivery of corrective genetic material directly into cHSPCs circulating in newborn osteopetrotic mice. This innovative approach bypasses the need for ex vivo manipulation of stem cells, aiming to restore gene function systemically by exploiting the natural trafficking dynamics of HSPCs during postnatal development. The methodology leverages engineered viral vectors adept at safely delivering therapeutic genes into target cells with high efficiency, integrating into the genome to allow sustained gene expression and cellular correction.

Experimental results demonstrate that in vivo LV-mediated gene therapy significantly extends the survival of osteopetrotic neonatal mice, a critical proof of concept indication that early postnatal genetic intervention can alter the disease trajectory. Gene-corrected HSPCs engrafted in vivo were shown to differentiate effectively into osteoclasts possessing functional bone resorption capacity. This functional recovery signifies a key milestone, as the restoration of osteoclast activity is essential for the remodeling of aberrant osteopetrotic bone and re-establishing a healthy BM microenvironment conducive to hematopoiesis.

Despite these encouraging outcomes, the study underlines that complete phenotypic rescue remains elusive within the parameters of the current experimental framework. The aggressive and rapidly progressing nature of osteopetrosis in this murine model imposes formidable challenges for full disease reversal. The findings underscore the critical need for optimization of gene transfer efficiency, vector design, and potentially combinatorial therapeutic strategies to achieve complete functional recovery in severe genetic bone diseases.

Intriguingly, the research highlights the mechanistic interplay between the impaired osteoclastogenesis inherent in osteopetrosis and the consequent perturbation of HSPC BM homing. Understanding this bidirectional crosstalk not only informs therapeutic targeting but also deepens the biological insight into how skeletal pathology intricately influences hematopoietic dynamics. These insights could have broader implications for other bone marrow niche disorders where cellular microenvironment and stem cell trafficking are disrupted.

The delivery of LV vectors in vivo shortly after birth presents a paradigm shift from conventional ex vivo gene therapy approaches, which often necessitate hazardous myeloablative conditioning and complex cell processing. By capitalizing on the natural postnatal mobilization of HSPCs into peripheral circulation, this method promises a less invasive, more readily translatable intervention that could be adapted for a spectrum of genetic diseases affecting blood and immune cells.

Furthermore, the robustness of this strategy was evaluated by detailed phenotypic analyses, showcasing the differentiation capacity of gene-corrected HSPCs into functional osteoclasts within the native BM microenvironment. Corrected osteoclasts demonstrated the ability to form resorption lacunae, a hallmark of their bone remodeling functionality, which is critical for reversing the osteopetrotic bone phenotype. This functional evidence consolidates the therapeutic relevance of early in vivo gene transfer for skeletal genetic disorders.

Nonetheless, the rapid disease progression and severity in this osteopetrotic mouse model presented significant obstacles, limiting the extent of therapeutic benefit achievable in a single intervention. Future research avenues include refining vector tropism and expression kinetics, enhancing transduction efficiency in target cells, and timing optimization to maximize the therapeutic window. The exploration of adjunctive agents promoting osteoclast differentiation or BM niche modulation may also amplify gene therapy efficacy.

These findings herald a new frontier in regenerative medicine by demonstrating that early postnatal in vivo gene therapy can penetrate systemically to correct a complex inherited disorder involving both hematopoietic and skeletal systems. They open avenues for clinical translation in treating patients with osteopetrosis and related conditions, aiming to circumvent the constraints posed by conventional therapies that rely heavily on donor availability and pre-conditioning regimens.

The comprehensive study provides a critical foundation for further development of postnatal gene therapy modalities that leverage stem cell trafficking patterns intrinsic to early life stages. It challenges the existing dogma requiring ex vivo manipulations and expands the therapeutic horizon for addressing congenital disorders with lethal or debilitating phenotypes manifesting soon after birth.

In conclusion, this research marks a transformative stride in understanding and harnessing postnatal hematopoietic stem cell biology for gene therapy, demonstrating significant survival benefits and partial phenotypic correction in a severe osteopetrosis mouse model. Continued investigation and technological refinements will be imperative to translate these promising preclinical results into viable clinical interventions that can change the lives of patients born with these devastating genetic diseases.

Subject of Research:
In vivo lentiviral-mediated gene therapy targeting hematopoietic stem and progenitor cells in an osteopetrosis mouse model to correct bone marrow failure and impaired osteoclast function.

Article Title:
In vivo haemopoietic stem cell gene therapy enabled by postnatal trafficking

Article References:
Milani, M., Fabiano, A., Perez-Rodriguez, M. et al. In vivo haemopoietic stem cell gene therapy enabled by postnatal trafficking. Nature (2025). https://doi.org/10.1038/s41586-025-09070-3

Image Credits: AI Generated